CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Rachel Ellingson

Senior Vice President & Chief Administrative Officer, Zimmer Biomet

Search every verified Rachel Ellingson interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Rachel Ellingson, currently chief strategy and corporate development officer at Solventum, discussed her role and the company's trajectory in a June 2025 episode of the DeviceTalks Weekly Podcast, recorded at DeviceTalks Minnesota. She compared her experience leading Solventum, a business spun out from 3M Healthcare, with her prior work at Zimmer Biomet during the ZimVie spinout. Ellingson described the process of disentangling from a parent company as difficult but energizing, noting that former divisions can chart their own path. She also stated that Solventum was focused on its current divestiture and on identifying areas within the rest of the business to invest in, adding that she would "never say never" regarding future acquisitions but that this was not the current focus. In a December 2023 episode of the Ortho Innovation Talks podcast, while serving as senior vice president and chief strategy officer at Zimmer Biomet, Ellingson outlined the company's growth strategy, which included both addition through innovation and acquisition and subtraction through exiting lower-growth, non-core businesses. She discussed the decision to spin off Zimmer Biomet's spine and dental businesses and the work required to create a new public company. Ellingson also described her responsibilities in corporate strategy, business development, and integration, including setting corporate goals, conducting market research and peer benchmarking, and embedding business development functions within the company's businesses.

Recent appearances

  • Ellingson Shares Solventum’s Next Steps, Baxter’s Mirza on its Co...

    June 27, 2025 · 📺 DeviceTalks

    In this episode of the DeviceTalks Weekly Podcast, host Tom Salemi sits down with Rachel Ellingson, chief strategy and corporate development officer at Solventum, recorded live at DeviceTalks Minnesota. Ellingson shares a rare perspective on leading medical device companies through major transitions, drawing on her experience at Zimmer Biomet during the ZimVie spinout and now at the helm of a business spun out from 3M Healthcare. She compares the two experiences and outlines what’s ahead for Solventum. In our Future of MedTech Opportunities (FOMO) segment, Kayleen Brown speaks with Athar Mirz…

    Watch on YouTube ↗

  • S1 Ep 1 - Zimmer Biomet's Rachel Ellingson on driving growth through portfolio shifts and M&A

    January 03, 2024 · 📺 DeviceTalks

    In the inaugural episode of Ortho Innovation Talks: Zimmer Biomet, Rachel Ellingson, SVP and Chief Strategy Officer at Zimmer Biomet, shares insights into the company's growth strategy, emphasizing that growth can be achieved not only through addition - like innovation and acquisition - but also through subtraction, such as exiting lower growth, non-core businesses. In the episode, Ellingson discusses the decision to spin off Zimmer Biomet's spine and dental businesses and the significant undertaking required to create a new public company, which required integrating and then disintegrating b…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →